Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Gimotty PA, Shore R, Lozon NL, Whitlock J, He S, Vigneau FD, Dickie L, Elder DE, Xu X, Schwartz AG, Guerry D.

J Invest Dermatol. 2016 Nov;136(11):2168-2172. doi: 10.1016/j.jid.2016.05.121. Epub 2016 Jun 25.

2.

Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.

Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC.

Ann Surg Oncol. 2016 Jan;23(1):250-6. doi: 10.1245/s10434-015-4766-y. Epub 2015 Jul 28.

3.

Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma.

Xu X, Gimotty PA, Guerry D, Karakousis G, Elder DE.

Methods Mol Biol. 2014;1102:275-86. doi: 10.1007/978-1-62703-727-3_15.

4.

Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy.

Bartlett EK, Gupta M, Datta J, Gimotty PA, Guerry D, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Mar;21(3):1016-23. doi: 10.1245/s10434-013-3388-5. Epub 2013 Nov 21.

5.

Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.

Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X, Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC.

Ann Surg Oncol. 2014 Feb;21(2):643-9. doi: 10.1245/s10434-013-3313-y. Epub 2013 Oct 12.

6.

Local immune response predicts survival in patients with thick (t4) melanomas.

Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G.

Ann Surg Oncol. 2013 Oct;20(11):3610-7. doi: 10.1245/s10434-013-3086-3. Epub 2013 Jul 10.

PMID:
23838911
7.

Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma.

Xu X, Chen L, Guerry D, Dawson PR, Hwang WT, VanBelle P, Elder DE, Zhang PJ, Ming ME, Schuchter L, Gimotty PA.

Clin Cancer Res. 2012 Jan 1;18(1):229-37. doi: 10.1158/1078-0432.CCR-11-0490. Epub 2011 Nov 17.

8.

Sunbeds and sunlamps: who used them and their risk for melanoma.

Fears TR, Sagebiel RW, Halpern A, Elder DE, Holly EA, Guerry D 4th, Tucker MA.

Pigment Cell Melanoma Res. 2011 Jun;24(3):574-81. doi: 10.1111/j.1755-148X.2011.00842.x. Epub 2011 Mar 29.

9.

High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Zhang PJ, Guerry D, Xu X.

Am J Surg Pathol. 2011 Feb;35(2):235-42. doi: 10.1097/PAS.0b013e3182036ccd.

10.

Prognostication in thin cutaneous melanomas.

Gimotty PA, Guerry D.

Arch Pathol Lab Med. 2010 Dec;134(12):1758-63. doi: 10.1043/2009-0653-RAR.1. Review.

PMID:
21128772
11.

Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?

Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, Rebbeck TR.

Cancer. 2010 May 15;116(10):2416-28. doi: 10.1002/cncr.24994.

12.

Characteristics associated with early and late melanoma metastases.

Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, Ming ME.

Cancer. 2010 Jan 15;116(2):415-23. doi: 10.1002/cncr.24724.

13.

Therapeutic effect of sentinel lymph node biopsy in melanoma remains an open question.

Gimotty PA, Yoon F, Hammond R, Rosenbaum P, Guerry D.

J Clin Oncol. 2009 Sep 10;27(26):4236-8. doi: 10.1200/JCO.2009.23.4518. Epub 2009 Aug 10. No abstract available.

14.

Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, Elder DE.

Hum Pathol. 2008 Jun;39(6):901-9. doi: 10.1016/j.humpath.2007.10.017. Epub 2008 Apr 28.

15.

Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients.

Gimotty PA, Guerry D, Flaherty K.

J Clin Oncol. 2008 Feb 1;26(4):517-8. doi: 10.1200/JCO.2007.14.3156. No abstract available.

PMID:
18235111
16.

Eruptive disseminated Spitz nevi.

Levy RM, Ming ME, Shapiro M, Tucker M, Guerry D 4th, Cirillo-Hyland VA, Elenitsas R.

J Am Acad Dermatol. 2007 Sep;57(3):519-23. Epub 2007 Apr 30. Review.

PMID:
17467853
17.

Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.

Swoboda RK, Somasundaram R, Caputo L, Ochoa EM, Gimotty PA, Marincola FM, Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter L, Vonderheide RH, Herlyn D.

Cancer Res. 2007 Apr 15;67(8):3555-9.

18.

Identification of high-risk patients among those diagnosed with thin cutaneous melanomas.

Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D.

J Clin Oncol. 2007 Mar 20;25(9):1129-34.

PMID:
17369575
19.

Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.

Karakousis GC, Gimotty PA, Czerniecki BJ, Elder DE, Elenitsas R, Ming ME, Fraker DL, Guerry D, Spitz FR.

Ann Surg Oncol. 2007 May;14(5):1596-603. Epub 2007 Feb 7.

PMID:
17285396
20.

Reproductive risk factors for cutaneous melanoma in women: a case-control study.

Lea CS, Holly EA, Hartge P, Lee JS, Guerry D 4th, Elder DE, Halpern A, Sagebiel RW, Tucker MA.

Am J Epidemiol. 2007 Mar 1;165(5):505-13. Epub 2006 Dec 8.

PMID:
17158470
21.

Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.

Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA.

Cancer. 2006 Nov 15;107(10):2436-45.

22.

Differentiation of normal skin and melanoma using high resolution hyperspectral imaging.

Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D 4th, Herlyn M, Elder DE, El-Deiry WS.

Cancer Biol Ther. 2006 Aug;5(8):1033-8. Epub 2006 Aug 9.

PMID:
16931902
23.

Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.

Fears TR, Guerry D 4th, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA.

J Clin Oncol. 2006 Aug 1;24(22):3590-6. Epub 2006 May 25.

PMID:
16728488
24.

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D.

Cancer Res. 2006 Mar 15;66(6):3287-93.

25.

Predictors of regional nodal disease in patients with thin melanomas.

Karakousis GC, Gimotty PA, Botbyl JD, Kesmodel SB, Elder DE, Elenitsas R, Ming ME, Guerry D, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2006 Apr;13(4):533-41. Epub 2006 Mar 7.

PMID:
16523360
26.

Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D.

Eur J Immunol. 2006 Feb;36(2):457-67.

27.

Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features.

Elder DE, Gimotty PA, Guerry D.

Dermatol Ther. 2005 Sep-Oct;18(5):369-85. Review.

PMID:
16297012
28.

CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma.

Somasundaram R, Caputo L, Guerry D, Herlyn D.

J Transl Med. 2005 Nov 10;3:41.

29.

A population-based validation of the American Joint Committee on Cancer melanoma staging system.

Gimotty PA, Botbyl J, Soong SJ, Guerry D.

J Clin Oncol. 2005 Nov 1;23(31):8065-75.

PMID:
16258105
30.

Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.

Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D.

J Clin Oncol. 2005 Nov 1;23(31):8048-56.

PMID:
16258103
31.

Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.

Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR.

Ann Surg Oncol. 2005 Jun;12(6):449-58. Epub 2005 Apr 19.

PMID:
15864482
32.

CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D.

J Immunol. 2005 May 1;174(9):5856-63.

33.

Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.

Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry D 4th, Hartge P, Struewing JP, Hogg D, Halpern A, Sagebiel RW, Tucker MA.

Cancer. 2004 Dec 15;101(12):2809-16.

34.

Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.

Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D.

J Clin Oncol. 2004 Sep 15;22(18):3668-76. Epub 2004 Aug 9. Erratum in: J Clin Oncol. 2005 Jan 20;23(3):656.

PMID:
15302909
35.

Diet and melanoma in a case-control study.

Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D 4th, Holly EA, Sagebiel RW, Potischman N.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1042-51.

36.

Melanoma seeding of an EUS-guided fine needle track.

Shah JN, Fraker D, Guerry D, Feldman M, Kochman ML.

Gastrointest Endosc. 2004 Jun;59(7):923-4. No abstract available.

PMID:
15173817
37.

Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach.

Kanetsky PA, Ge F, Najarian D, Swoyer J, Panossian S, Schuchter L, Holmes R, Guerry D, Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):808-19.

38.

First international melanoma research congress.

Herlyn M, Guerry D 4th.

Cancer Biol Ther. 2003 Nov-Dec;2(6):721-4. No abstract available.

PMID:
14688485
39.

Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice.

Li J, Li W, Liang S, Cai D, Kieny MP, Jacob L, Linnenbach A, Abramczuk JW, Bender H, Sproesser K, Swoboda R, Somasundaram R, Guerry D, Herlyn D.

J Immunol. 2003 Sep 15;171(6):2922-9.

40.

Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside.

Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D.

Cancer Immunol Immunother. 2003 Mar;52(3):145-54. Epub 2003 Feb 11.

PMID:
12649743
41.

A CD4+, HLA-DR7-restricted T-helper lymphocyte clone recognizes an antigen shared by human malignant melanoma and glioma.

Somasundaram R, Swoboda R, Caputo L, Lee A, Jackson N, Marincola FM, Guerry D, Herlyn D.

Int J Cancer. 2003 Apr 10;104(3):362-8.

42.

Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy.

Anderson TD, Weber RS, Guerry D, Elder D, Schuchter L, Loevner LA, Rosenthal DI.

Head Neck. 2002 Dec;24(12):1068-71.

PMID:
12454945
43.

Validation of prognostic models for melanoma.

Gimotty PA, Guerry D, Elder DE.

Am J Clin Pathol. 2002 Oct;118(4):489-91. Review. No abstract available.

PMID:
12375633
44.

P gene as an inherited biomarker of human eye color.

Rebbeck TR, Kanetsky PA, Walker AH, Holmes R, Halpern AC, Schuchter LM, Elder DE, Guerry D.

Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):782-4.

45.

Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk.

Fears TR, Bird CC, Guerry D 4th, Sagebiel RW, Gail MH, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA.

Cancer Res. 2002 Jul 15;62(14):3992-6.

46.

Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic.

McGinnis KS, Lessin SR, Elder DE, Guerry D 4th, Schuchter L, Ming M, Elenitsas R.

Arch Dermatol. 2002 May;138(5):617-21.

PMID:
12020222
47.

Multiple primary melanoma revisited.

Blackwood MA, Holmes R, Synnestvedt M, Young M, George C, Yang H, Elder DE, Schuchter LM, Guerry D, Ganguly A.

Cancer. 2002 Apr 15;94(8):2248-55.

48.

A polymorphism in the agouti signaling protein gene is associated with human pigmentation.

Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR.

Am J Hum Genet. 2002 Mar;70(3):770-5. Epub 2002 Feb 6.

49.

Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma.

Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):509-13.

50.

Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study.

Wildemore JK 4th, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D 4th, Lessin SR, Elder DE, Bucky LP.

Ann Plast Surg. 2001 May;46(5):488-94.

PMID:
11352421

Supplemental Content

Loading ...
Support Center